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of postdoctoral training, are comparable to trainees in the special-
ties noted above.
We believe that efforts to gerrymander qualification boundaries
to exclude able practitioners from practice work against, rather
than foster, a culture of multidisciplinary collaborative care. We
who developed these guidelines—including multiple physicians
with pediatric CCM certification—did not do so hoping to attain
a self-bestowed hegemony for deciding what constitutes acceptable
cardiac intensive care training. Rather, we called on many years of
experience in an effort to formulate guidelines to prepare a
pediatric cardiologist to be expert in managing critically ill cardiac
patients, recognizing that various disciplines, such as pediatric
CCM, will employ other training models. No doubt cardiac
intensivists will benefit from consultation with CCM colleagues, as
will also happen in reverse—a robust culture of multidisciplinary
care being essential regardless of the pathway chosen to become a
cardiac intensivist.
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Diagnosis and Management
of Chronic Heart Failure
The American College of Cardiology/American Heart Association
(ACC/AHA) 2005 guideline update for the diagnosis and man-
agement of chronic heart failure in the adult recently published
in the Journal (1) states that the addition of a combination of
isosorbide dinitrate and hydralazine to conventional therapy is
strongly recommended (class IIa) with a high level of evidence
(level A) for patients who have persistent symptoms without
making a distinction on the patient’s race.
Although in the complete version of the guideline (available on
JACC ’s Web site) it is pointed out that, based on the results of the
A-HeFT trial (2), there is not enough evidence to extrapolate the
results obtained in black people to the general population; neither the
abbreviated nor the complete guideline includes this limitation in the
recommendations. To avoid misunderstandings, we believe that this
fact should explicitly be reported in both the shortened and complete
versions of the guideline when the recommendation of adding
isosorbide dinitrate and hydralazine to conventional therapy is made.
As pointed out above, the recommendation of adding isosorbide
dinitrate and hydralazine is based on only one controlled, random-
ized trial (2). It is surprising that the effect of the addition of an
angiotensin receptor blocker (ARB) in symptomatic patients who
are already being treated with conventional therapy, also evaluated
only in one controlled, randomized trial (3), has been considered as
a class IIb recommendation with a level of evidence B despite the
important benefits showed in the CHARM-Added trial (3).
An additional comment concerns the use of nebivolol in heart
failure. In the 2005 guideline there is no mention of nebivolol in
heart failure treatment. Nebivolol, a beta1 selective blocker with
vasodilating properties due to nitric oxide modulation, was tested
in the SENIORS trial (4) and extended the evidence of beta-
blockers’ benefits to a broad population of elderly patients with
heart failure. The effect of nebivolol has been tested only in one
trial involving elderly patients, but if other drug therapies are
recommended based on one-trial evidence we believe that nebivo-
lol should, at least, be mentioned as an option in elderly patients
with heart failure.
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